FindMyRecallSubscribe
Class II: temporary or reversible health riskCompleted

Imprimis NJOF Epinephrine Lidocaine HCL Recall

Epinephrine Lidocaine HCL, 0

Imprimis NJOF, LLC · Ledgewood, NJ

Risk level
Class II
Reported by FDA
Jul 30, 2025
Recall ID
D-0535-2025
Check your lot numberHow we source this data

Summary

Imprimis NJOF recalled Epinephrine Lidocaine HCL starting Jul 9, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0535-2025 on Jul 30, 2025. Reason: Sub-Potent Drug: Subpotent assay results during stability testing. Status: Completed.

Why it was recalled

Sub-Potent Drug: Subpotent assay results during stability testing.

Product description

Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01

Lot numbers, UPCs & expiration codes

Lot: 24DEC017, Exp. 07/12/2025.

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0535-2025
Classification
Class II
Status
Completed
Recall initiated
Jul 9, 2025
FDA report date
Jul 30, 2025
Quantity
6,880 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Imprimis NJOF, LLC

Original FDA data

Every field from FDA enforcement report D-0535-2025, exactly as published.

Show all FDA fields
City
Ledgewood
State
NJ
Status
Completed
Country
United States
Event ID
97183
Address
1705 Route 46 Ste 6B
Code information
Lot: 24DEC017, Exp. 07/12/2025.
Postal code
07852-9720
Report date
Jul 30, 2025
Product type
Drugs
Recall number
D-0535-2025
Classification
Class II
Recalling firm
Imprimis NJOF, LLC
Product quantity
6,880 vials
Reason for recall
Sub-Potent Drug: Subpotent assay results during stability testing.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Epinephrine Lidocaine HCL, 0.25mg/mL and 7.5 mg/mL, 20x1 mL Vials per carton, Rx Only, Imprimis NJOF, 1705 Route 46 West, Unit 6B Ledgewood, NJ, 07852 NDC: 71384-641-01
Distribution pattern
Nationwide in the USA
Recall initiation date
Jul 9, 2025
Initial firm notification
Letter
Center classification date
Jul 21, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0535-2025, published Jul 30, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls